Jennifer Brown
, Director of the · Mass General Brigham
Credentials: · · · ·
History
- Present
Chronic Lymphocytic Leukemia (CLL) Center · Mass General Brigham
- 2003–2004
Hematology
- 2001–2003
- 1994–1998
Research
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Review · Molecular Cancer · 2023 · 1,738 citations
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2016 · 1,585 citations
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
New England Journal of Medicine · 2014 · 1,369 citations
80 papers · 3 as a fellow
48 papers
46 papers
- JB
45 papers
- SO
45 papers
37 papers
37 papers · 3 as a fellow
31 papers
Grants
- 1978–2027
Physician Scientist Training in Cancer Research
National Cancer Institute · T32
PI · $2.3M · Dana-Farber Cancer Inst
- 2021–2027
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)
National Cancer Institute · R01
Contact PI · $3.1M · Dana-Farber Cancer Inst
- 2017–2023
Unlocking the Potential of PI3K Inhibition in CLL
National Cancer Institute · R01
Contact PI · $2.9M · Dana-Farber Cancer Inst
- 2016–2021
Comprehensive Dissection of the CLL Genome & Phenome to Improve Patient Outcomes
National Cancer Institute · P01
Project lead · $1.7M · Dana-Farber Cancer Inst
Clinical trials
- 2025–2032
Principal investigator · Recruiting · Phase 1, Phase 2
Jennifer R. Brown, MD, PhD
- 2020–2028
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Principal investigator · Active not recruiting · Phase 2
Jennifer R. Brown, MD, PhD
- 2016–2027
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
- 2014–2020
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute